by John Conrad | May 28, 2024 | NewsBrief
Eli Lilly and Company just announced a massive $9 billion investment in a new manufacturing site in Lebanon, Indiana. This represents an increase from the initially planned $3.7 billion investment at the same site, more than doubling Lilly’s commitment. The...
by John Conrad | May 28, 2024 | Member News
MAIA Biotechnology, a cutting-edge biopharmaceutical company, is pioneering a novel approach to cancer treatment that could revolutionize the field of oncology. Their premier drug candidate, THIO, is a first-in-class telomere-targeting agent designed to selectively...
by John Conrad | May 24, 2024 | Member News
AbbVie announced today that it has completed its previously disclosed acquisition of Landos Biopharma, Inc. With this transaction now closed, Landos and its lead investigational asset NX-13 for inflammatory bowel disease (IBD) have become part of AbbVie’s...
by John Conrad | May 23, 2024 | Member News
The National Science Foundation (NSF) has launched a new $1.2 million pilot aimed at accelerating breakthrough technologies by connecting industry innovators with researchers at emerging research institutions. The 18-month pilot will be led by Halo, an AI platform...
by John Conrad | May 22, 2024 | Member News
The life sciences sector in the U.S. is experiencing a turning point. JLL’s first U.S. Life Sciences Property Report indicates a rise in lab space demand after a period of softening. This positive trend is fueled by several factors, making the coming months...
by John Conrad | May 21, 2024 | Member News
Crain’s reported that Chicago’s AI-powered darling, Tempus, finally filed for an initial public offering (IPO) today. Founded in 2015 by Eric Lefkofsky, the company started by offering genomic sequencing for cancer treatment but has expanded to tackle other...
